C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 814—Premarket Approval of Medical DevicesSubpart E—Postapproval Requirements

21 C.F.R. § 814.80 (2026)

General

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1993–2025 78citing cases
At a glance

Courts have cited this section in 78 opinions since 1993, 7 of them in the last five years.

A device may not be manufactured, packaged, stored, labeled, distributed, or advertised in a manner that is inconsistent with any conditions to approval specified in the PMA approval order for the device.

The 20 cases that cite 21 C.F.R. § 814.80 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENBarbara E. Horn v. Thoratec Corp., 376 F.3d 163 (3d Cir. 2004).
cites § 814.80 3×cited by 101 cases
Where it cites § 814.80
“Similarly, her failure-to-warn claims would require TCI to provide different warnings and instructions from those approved by the FDA.”
The case’s holding
State law failure-to-warn claims are preempted when they require a manufacturer to provide different warnings or instructions than those approved through the FDA pre-market approval process.
Later courts cite it for
“an agency may change its course so long as it can justify its change with a 'reasoned analysis.” · 3 citing courts
2
GREENJoseph Mink v. Smith & Nephew, Inc., 860 F.3d 1319 (11th Cir. 2017).
cites § 814.80 2×cited by 68 cases
Where it cites § 814.80
“And he pointed to device-specific federal requirements he says S&N violated, including the premarket approval specifications for the device, see 21 C.F.R. § 814.80 , as well as a number of other specific federal regulations.”
The case’s holding
A state law claim is not preempted if the plaintiff alleges a breach of a well-recognized duty that parallels federal requirements.
Later courts cite it for
“to make it through, a plaintiff has to sue for conduct that violates a federal requirement (avoiding express preemption), but cannot sue only because the conduct violated that federal requirement (avoiding implied preemption).” · 11 citing courts
3
GREENWalter Shuker v. Smith & Nephew PLC, 885 F.3d 760 (3d Cir. 2018).
cites § 814.80 1×cited by 250 cases
Where it cites § 814.80
“" 21 C.F.R. § 814.80 . To that end, a manufacturer wishing to make "incremental change[s]" that affect the device's safety and effectiveness must submit a supplemental premarket approval application.”
The case’s holding
Specific personal jurisdiction requires a defendant to deliberately target the forum state rather than merely participating in a stream of commerce.
Later courts cite it for
“efforts to exploit a national market that necessarily includes pennsylvania are insufficient” · 9 citing courts
4
GREENRamirez v. Medtronic Inc., 961 F. Supp. 2d 977 (D. Ariz. 2013).
cites § 814.80 3×cited by 46 cases
Where it cites § 814.80
“§ 331 (a); see also 21 C.F.R. § 814.80 (providing that a “device may not be .”
The case’s holding
Federal preemption does not bar state law claims arising from a medical device manufacturer's promotion of off-label uses that have not been reviewed by the FDA.
Later courts cite it for
“affirmation that forms the basis of an express warranty must be between the seller and the buyer.” · 2 citing courts
5
GREENGomez v. St. Jude Med. Daig Div. Inc., 442 F.3d 919 (5th Cir. 2006).
cites § 814.80 2×cited by 113 cases
Where it cites § 814.80
“, 21 C.F.R. § 814.80 (prohibiting the production or labeling of any device in a manner inconsistent with any conditions of approval specified in the approval order); 21 C.”
The case’s holding
State-law design, warning, and training claims for medical devices are preempted if they displace the FDA's exclusive role or impose requirements that parallel or enforce federal regulations.
Later courts cite it for
“the district judge properly limited gomez's negligence claims to a claim that the medical device used in her surgery was defectively manufactured because it did not comply with the fda-approved specifications.” · 3 citing courts
6
GREENRiley v. Cordis Corp., 625 F. Supp. 2d 769 (D. Minn. 2009).
cites § 814.80 2×cited by 110 cases
Where it cites § 814.80
“A Class III device may not be labeled in a manner that is inconsistent with any conditions specified in its PMA, 21 C.F.R. § 814.80 , and once a device has received PMA, a manufacturer generally needs FDA approval before making changes to the labeling that would affect safety or…”
The case’s holding
A state-law claim survives preemption only if it is premised on conduct that violates the FDCA and would give rise to a recovery under state law without the FDCA.
Later courts cite it for
“must be the type of conduct that would traditionally give rise to liability under state law-and that would give rise to liability under state law even if the fdca had never been enacted.” · 8 citing courts
7
GREENWorthy v. Collagen Corp., 967 S.W.2d 360 (Tex. 1998).
cites § 814.80 3×cited by 68 cases
Where it cites § 814.80
“” 21 C.F.R. § 814.80 . A device manufacturer must promptly report to the FDA any malfunctions of a device or any deaths or serious injuries caused by it.”
The case’s holding
State law claims alleging liability despite a medical device's adherence to FDA-approved standards are preempted by federal requirements.
Later courts cite it for
“while a federal requirement would ordinarily not preempt general state common law requirements such as a duty of care or a duty to warn in the abstract, a federal requirement would preempt a particularized application of such duties that imposed a specific 'standard of care or behavior' different or in addition to the federal requirement.” · 3 citing courts
8
GREENCaplinger v. Medtronic, Inc., 784 F.3d 1335 (10th Cir. 2015).
cites § 814.80 2×cited by 56 cases
Where it cites § 814.80
“§§ 351, 352; see also 21 C.F.R. § 814.80 (forbidding devices to be “manufactured, packaged, stored, labeled, distributed, or advertised in a manner that is inconsistent with any conditions to approval specified in the PMA approval order for the device”).”
The case’s holding
The Medical Device Amendments preempt state law tort claims that impose new safety or effectiveness requirements on a federally approved device, regardless of whether the claim involves off-label use.
Later courts cite it for
“a district court may grant judgment as a matter of law under federal rule of civil procedure 12(b)(6) on the basis of an affirmative defense like preemption when the law compels that result.” · 6 citing courts
9
GREENColeman v. Medtronic, Inc., 223 Cal. App. 4th 413 (Ct. App. 2014).
cites § 814.80 2×cited by 39 cases
Where it cites § 814.80
“(§ 331(a); see 21 C.F.R. § 814.80 (2013) [providing that a “device may not be .”
The case’s holding
State tort claims are not preempted by federal law if they are based on a manufacturer's failure to comply with parallel federal requirements such as reporting adverse events.
Later courts cite it for
“will ultimately have to prove that if a defendant had properly reported the adverse events to the fda as required under federal law, that information would have reached the plaintiff's doctors in time to prevent plaintiff's injuries.” · 3 citing courts
10
GREENIn re Medtronic, Inc., Sprint Fidelis Leads, 623 F.3d 1200 (8th Cir. 2010).
cites § 814.80 1×cited by 215 cases
Where it cites § 814.80
“(internal quotations and citation omitted); see also 21 C.F.R. § 814.80 ("A device may not be manufactured, packaged, stored, labeled, distributed, or advertised in a manner that is inconsistent with any conditions to approval specified in the PMA approval order for the device.”
The case’s holding
To avoid preemption, a plaintiff must allege conduct that violates a specific federal requirement without suing solely because the conduct violates federal regulations.
Later courts cite it for
“post-dismissal motions to amend are disfavored.” · 11 citing courts
11
GREENGravitt v. Mentor Worldwide, LLC, 289 F. Supp. 3d 877 (E.D. Ill. 2018).
cites § 814.80 2×cited by 11 cases
Where it cites § 814.80
“In connection with that approval, and pursuant to its authority under 21 C.F.R. §§ 814.80 and 814.82, the FDA required Mentor to conduct six-post approval studies designed to address issues not raised during the PMA process.”
12
GREENBeavers-Gabriel v. Medtronic, Inc., 15 F. Supp. 3d 1021 (D. Haw. 2014).
cites § 814.80 2×cited by 26 cases
Where it cites § 814.80
“” 21 C.F.R. § 814.80 (emphasis added). The PMA approval letter for the Infuse Device provides that the Infuse Device “is indicated for spinal fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one level from L4-S1,” and the “Bone…”
The case’s holding
State-law design defect claims are expressly preempted when success requires proving an FDA-approved medical device should have been designed differently.
Later courts cite it for
“ramirez has been rejected - for good reason - by numerous courts.” · 5 citing courts
13
GREENMcLaughlin v. Bayer Corp., 172 F. Supp. 3d 804 (E.D. Pa. 2016).
cites § 814.80 1×cited by 33 cases
Where it cites § 814.80
“See-21 C.F.R. 814.80 (prohibiting a device from being labeled, advertised,.”
The case’s holding
A negligence claim against a medical device manufacturer is not preempted if it parallels federal requirements and plausibly alleges duty, breach, causation, and actual damages.
Later courts cite it for
“(1) a duty owed to the plaintiff by the defendant; (2) a breach of that duty; (3) a causal connection between the breach and resulting injury; and (4) actual loss or damages.” · 3 citing courts
14
GREENRiegel v. Medtronic, Inc., 451 F.3d 104 (2d Cir. 2006).
cites § 814.80 1×cited by 104 cases
Where it cites § 814.80
“21 C.F.R. § 814.80 (“A device may not be manufactured, packaged, stored, labeled, distributed, or advertised in a manner that is inconsistent with any conditions to approval specified in the PMA approval order for the device.”
The case’s holding
State common law tort claims alleging liability based on a medical device's adherence to FDA premarket approval standards are preempted by the Medical Device Amendments.
Later courts cite it for
“an expert opinion requires some explanation as to how the expert came to his conclusion and what methodologies or evidence substantiate that conclusion.” · 26 citing courts
15
GREENHughes v. Boston Sci. Corp., 631 F.3d 762 (5th Cir. 2011).
cites § 814.80 1×cited by 97 cases
Where it cites § 814.80
“§§ 360c-360j; 21 C.F.R. §§ 814.80 , 814.82. If a manufacturer fails to comply with the FDA regulations or postapproval conditions, the FDA has the power to withdraw PMA approval, as well as the power to impose other remedies such as additional warnings or corrective labeling.”
The case’s holding
A state failure-to-warn claim is not preempted if it is predicated on a manufacturer's violation of federal medical device reporting regulations.
Later courts cite it for
“did not depend on speculation that the fda would have taken any particular regulatory action in response to violation of the regulations at issue, as in buckman .” · 3 citing courts
16
GREENThorn v. Medtronic Sofamor Danek, USA, Inc., 81 F. Supp. 3d 619 (W.D. Mich. 2015).
cites § 814.80 2×cited by 20 cases
Where it cites § 814.80
“Courts have held that the FDCA’s misbranding provisions and 21 C.F.R. § 814.80 together constitute “the federal requirements” for purposes of Riegel’s second step.”
Later courts cite it for
“there is no state law duty to abstain from off-label promotion.” · 2 citing courts
17
GREENRollins v. St. Jude Med., 583 F. Supp. 2d 790 (W.D. La. 2008).
cites § 814.80 2×cited by 18 cases
Where it cites § 814.80
“, 21 C.F.R. § 814.80 (prohibiting the production or labeling of any device in a manner inconsistent with any conditions of approval specified in the approval order); 21 C.”
Later courts cite it for
“may take judicial notice of and consider the public records of the fda ... without transforming a motion to dismiss into a motion for summary judgment.” · 2 citing courts
18
GREENJennifer Stamps v. Collagen Corp., 984 F.2d 1416 (5th Cir. 1993).
cites § 814.80 1×cited by 136 cases
Where it cites § 814.80
“See also 21 C.F.R. § 814.80 ("A device may not be manufactured, packaged, stored, labeled, distributed, or advertised in a manner that is inconsistent with any conditions to approval specified in the PMA approval order for the device.”
The case’s holding
The Medical Device Amendments preempt state law claims for defective design, inadequate warnings, and negligence that impose requirements different from or in addition to federal safety standards.
Later courts cite it for
“be subject to recommendations, guidelines, post-marketing surveillance, the development of patient registries, and even the promulgation of specific performance standards, should the fda deem them a sufficient health hazard as to require strict product specifications or warnings.” · 5 citing courts
19
GREENHawkins v. Medtronic, Inc., 62 F. Supp. 3d 1144 (E.D. Cal. 2014).
cites § 814.80 2×cited by 12 cases
Where it cites § 814.80
“2014) (holding that “the FDCA prohibits ‘misbranding’ of medical devices, which includes either misleading labeling or misleading advertising of the medical device, and 21 C.F.R. § 814.80 prohibits Defendants from advertising the INFUSE® Device for uses beyond what is provided…”
20
GREENUnited States ex rel. Modglin v. DJO Global Inc., 48 F. Supp. 3d 1362 (C.D. Cal. 2014).
cites § 814.80 1×cited by 44 cases
Where it cites § 814.80
“that is adulterated or misbranded”); 21 C.F.R. § 814.80 (stating that once the FDA has approved a PMA application, the manufacturer of the approved device may not manufacture, package, store, label, distribute, or advertise the device in a manner that is inconsistent with any…”
The case’s holding
Nondisclosure of off-label use of a device is immaterial to Medicare reimbursement where Medicare coverage does not depend on on-label use; courts may judicially notice government websites.
Later courts cite it for
“under rule 201, the 22 court can take judicial notice of public records and government documents available from reliable sources on the internet, such as websites run by governmental 23 agencies.” · 5 citing courts

Show all 78 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199320092025

One bar per year. Tallest: 9 cases in 2014. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
5th Cir.4Cal. Ct. App.43rd Cir.38th Cir.3W.D. Ky.3D. Md.3D. Minn.3E.D. Wis.3

The 8 courts with the most citing cases, of 47 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Show all 78 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com